Production of Pfs25, a Plasmodium falciparum transmission-blocking vaccine target antigen, in functional conformation with the potential to elicit effective immunogenicity still remains a major challenge. In the current study, codon-harmonized recombinant Pfs25 (CHrPfs25) was expressed in Escherichia coli, and purified protein after simple oxidative refolding steps retained reduction-sensitive conformational epitopes of transmission-blocking monoclonal antibodies. CHrPfs25 formulated in several adjuvants elicited strong immunogenicity in preclinical studies in mice. Antibodies elicited after immunization recognized native Pfs25 on the surface of live gametes of P. falciparum and demonstrated complete malaria transmission-blocking activity. The transmission-blocking efficacy was 100% even after a 1:128 dilution of sera from immunized mice in the complete Freund's adjuvant and Montanide ISA51 groups and after a 1:16 dilution of sera from mice in the alum group. The blocking was mediated by antibodies; purified IgG at concentrations as low as 31.25 g/ml exhibited 100% transmission blocking in membrane feeding assays employing two different species of mosquitoes, Anopheles gambiae and Anopheles stephensi. This study provides the first evidence for successful expression of biologically functional rPfs25 in E. coli. The extremely potent malaria transmission-blocking activity of antibodies elicited by immunization with purified protein provides strong support for further evaluation of E. coli-derived CHrPfs25 as a malaria transmission-blocking vaccine in human clinical trials. N early half the world's population lives in regions where malaria is endemic, and this accounts for approximately 219 million clinical cases with up to 660,000 deaths, mostly of children under five years of age (1, 2). The parasite has displayed a remarkable ability to develop resistance to almost any antimalaria drug used, and there has been a recent report on artemisinin-resistant Plasmodium falciparum in Cambodia (3). While efforts to develop vaccines targeting various life cycle stages of the parasite are under way, in both the human host and the mosquito vector, none is available currently. Vaccines targeting the transmission stages of the parasites, the sexual stages, are considered essential to achieve the goal of gradual elimination of malaria. Malaria transmission reduction can be achieved either by blocking the development of gametocytes, the sexual stages of the parasite, or by reducing further development of these transmission stages in the mosquito vector (4-6). Recent emphasis on global elimination and eradication of malaria has outlined a critical role for a malaria transmission-blocking vaccine (TBV) as an effective tool for reducing malaria transmission.The long-term success of a TBV depends upon induction of high functional antibody titers in order to effectively block the parasite transmission cycle (7). In P. falciparum, Pfs230, Pfs48/45, and Pfs25 have been identified as target antigens, and antibodies directed against any o...